Literature DB >> 8784644

Antidepressant options: venlafaxine in perspective.

M E Thase1.   

Abstract

Depression is often related to disturbances of norepinephrine and serotonin neurochemical systems within the brain that affect functional neurobehavioral systems. Classes of antidepressant agents have been developed that directly affect proposed brain neurochemical alterations. Many of the differences among antidepressant agents, particularly in safety and tolerability, can be attributed to their differing effects on receptor blockade and neurotransmitter reuptake. The overall goal of antidepressant treatment is complete recovery, and three phases of treatment have been delineated. Because of the recurrent and potentially chronic nature of depression, safety and tolerability of available treatments are especially important. An overview of antidepressant options is presented, with a particular focus on venlafaxine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784644     DOI: 10.1097/00004714-199606002-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  4 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Anxiety and Depression: Optimizing Treatments.

Authors:  James C. Ballenger
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.